Final Appraisal Recommendation: Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) -

Final Appraisal Recommendation: Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
Information type: Drug best practice guidance
Source: All Wales Medicines Strategy Group
Specialities: Respiratory disorders
Summary
Fluticasone furoate/vilanterol (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with COPD with a FEV1< 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
UKMi comment
Fluticasone furoate/vilanterol (Relvar® Ellipta®) should be used in line with the NICE clinical guideline on COPD for the symptomatic treatment of adults.

The AWMSG Secretariat Assessment Report (ASAR) and a clinical expert summary are available via the links below.
Related links: Secretariat appraisal report Clinical expert summary NICE clinical guideline